PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.06
Positive D/E while TRVN shows negative equity. John Neff would examine our competitive advantages in a challenging market.
7.35
Net debt while TRVN maintains net cash position. John Neff would demand higher returns to justify the additional leverage risk.
-18.91
Negative coverage while TRVN shows 0.00. Joel Greenblatt would look for operating improvements and turnaround potential.
9.21
Current ratio exceeding 1.5x TRVN's 4.66. Charlie Munger would verify if this advantage translates to better supplier terms.
No Data
No Data available this quarter, please select a different quarter.